Progressive U.S. Lawmaker Advocates for Health and Tax Reform, But Why Invested in Coca-Cola Stocks?

Representative Lloyd Doggett, a senior Democrat overseeing tax and health policy in the U.S. House of Representatives, has disclosed a new purchase of The Coca-Cola Company (NYSE: KO) shares. On April 1, Doggett acquired between $1,001 and $15,000 worth of Coca-Cola stock (approximately ₩1.3 million to ₩20 million), a transaction that only appeared in his official trading report on May 6.

Coca-Cola, long regarded as a defensive stock dominating the global carbonated and non-carbonated beverage markets, has traded modestly below its one-year high of $82, rising about 3% from its April 1 close of $76.08 to $78.42 as of May 8. In its first-quarter earnings report released April 28, the company posted revenue growth of roughly 12% year-over-year and delivered earnings per share (EPS) of $0.86, beating analysts’ estimates and raising its full-year profit guidance. The results sparked a one-day stock jump of over 3%, buoying investor sentiment. However, Coca-Cola still faces significant tax risk—potentially up to $14 billion—stemming from an ongoing transfer-pricing dispute with the U.S. Internal Revenue Service.

Doggett serves on the House Ways and Means Committee, the Budget Committee and the bipartisan Joint Committee on Taxation. As Democratic ranking member of the Ways and Means health subcommittee, he has focused on Medicare, drug pricing and multinational tax avoidance. He also led a Prescription Drug Pricing Reduction Task Force aimed at lowering high medication costs. Given his advocacy for health-care and tax reform, his personal investment in a major sugar-sweetened beverage company—often cited in debates over public-health spending and obesity—creates a subtle tension with his political messaging.

Though the size of Doggett’s purchase falls well within legal limits, critics note a potential overlap between his committee roles and Coca-Cola’s complex overseas earnings and IRS dispute. As Congress debates stricter limits on individual stock trading by members, this high-profile progressive’s move into a large, defensive consumer stock may become a case study in future ethics, conflict-of-interest and regulatory discussions.